Satu K.
- Country
- Finland
- Department
- FVR, OULU CLINIC
Research Overview
- Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40
- Evaluation of Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections
- Evaluation of Safety and Immunogenicity of V116 in Pediatric Patients at Increased Risk for Pneumococcal Disease: A Phase 3 Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 160 of 461 partner sites.
Specializations
Respiratory Virus Research
Specializes in developing preventive solutions for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), with particular focus on vulnerable populations including infants and older adults. The investigator studies vaccine efficacy and immune responses in preventing respiratory tract infections.
- RSV vaccine immunogenicity
- Lower respiratory tract disease prevention
- Viral infection control in elderly populations
Bacterial Disease Prevention
Conducts research on vaccines targeting meningococcal and pneumococcal infections. Focuses on developing conjugate vaccines for multiple bacterial strains, particularly studying their effectiveness in pediatric populations.
- Multi-valent pneumococcal vaccines
- Meningococcal conjugate vaccines
- Pediatric immunization protocols
Viral Disease Management
Investigates preventive strategies for various viral conditions including influenza, cytomegalovirus, and herpes zoster. Specializes in vaccine development for different age groups, with particular attention to efficacy in older adults.
- Influenza vaccine development
- CMV infection prevention
- Long-term vaccine effectiveness
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.